We are a nationwide team of investigators, united by common goals.
University of Pittsburgh
University of Michigan
Temple University Hospital
Henry Ford Health/Wayne State University
University of Maryland Medical Center
University of North Carolina
Weill Cornell Medicine
University of California - San Francisco
University of Illinois - Chicago
UVA Medical Center
Detroit Medical Center
Cleveland Clinic
Northwestern Medical Center
Brigham and Women’s Hospital/Harvard University
University of Florida Medicine
University of California - Los Angeles
Emory University
Jackson Health System/University of Miami
University of Kansas Medical Center
Atrium Health Carolinas Medical Center
Houston Methodist Hospital
University of Wisconsin Hospitals
Oklahoma University Medical Center
PAM Health
Ochsner LSU Health
University of Colorado
Oregon Health and Science University
Vanderbilt University Medical Center
University of Kentucky
Virginia Commonwealth University
Ohio State University Wexner Medical Center
Binghamton University
RWJ University Hospitals/Rutgers University
UT Southwestern Medical Center
University of Arizona/Banner University Medical Center
Medical University of South Carolina
Roswell Park Comprehensive Cancer Center
Our
Focus
Our team is led by clinician-investigators that understand the major challenges to treatment of MDR infections and outstanding knowledge gaps in the field. Our network seeks to fill these knowledge gaps through robust comparative-effectiveness studies that are directly translatable to clinical practice.
Real Questions
Investigators at participating sites are highly-qualified investigators and internationally-recognized experts. Site investigators are essential to collect robust real-world clinical data that represent commonly-encountered clinical scenarios.
Real Data
Our
Advantage
Our comparative-effectiveness studies seek to define the optimal treatment approaches for MDR pathogens, and are supported by centralized microbiologic testing and whole-genome sequencing. These translational research efforts help to advance the management of patients infected by MDR pathogens.
Front line
Our network includes leading medical centers across 24 states. The sum of consortium is greater than any of the individual parts. Collaboration drives the success of the network, which is well-positioned to answer diverse scientific questions. Our studies leverage the power of the network to effectively power studies focused on the treatment of MDR pathogens.
We are many
Jason M. Pogue
PharmD, FIDP, FCCP, BCIDP
Dr. Pogue a Clinical Professor of Pharmacy at the University of Michigan College of Pharmacy. His research interests focus on the epidemiology and management of multi-drug resistant Gram-negative pathogens and antimicrobial stewardship.
Visit Dr. Pogue’s University of Michigan website here.
Ryan K. Shields
PharmD, MS
Dr. Shields is an Associate Professor of Medicine and Co-Director of the Center for Innovative Antimicrobial Therapy at the University of Pittsburgh. He is also the Co-Director of the UPMC Presbyterian stewardship program and Director of the ID fellowship stewardship track. His laboratory focuses on the characterization and suppression of antibiotic resistance against Gram-negative bacteria. His clinical and research interests are to design individualized treatment for patients infected by multidrug-resistant pathogens.
Visit Dr. Shields’ University of Pittsburgh website here.